Skip to Content

Join the 'Lymphangioleiomyomatosis' group to help and get support from people like you.

Lymphangioleiomyomatosis News

Related terms: LAM, Pulmonary Lymphangioleiomyomatosis

FDA Approves Rapamune (sirolimus) for Rare Lung Disease Lymphangioleiomyomatosis

Posted 1 Jun 2015 by Drugs.com

May 28, 2015 – The U.S. Food and Drug Administration today approved Rapamune (sirolimus), to treat lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that primarily affects women of childbearing age. This is the first drug approved to treat the disease. LAM is characterized by an abnormal growth of smooth muscle cells that invade lung tissues, including the airways, and blood/lymph vessels that cause destruction of the lung, resulting in airflow obstruction, and limiting the delivery of oxygen to the body. LAM is a very rare disease. According to the U.S. National Library of Medicine, only between two and five women per million women worldwide are known to have the disease. Rapamune, which is available as both a tablet and an oral solution, was originally approved in 1999 as an immunosuppressive agent to help prevent organ rejection in patients 13 years and older ... Read more

Related support groups: Sirolimus, Rapamune, Lymphangioleiomyomatosis

Ask a Question

Further Information

Related Condition Support Groups

Respiratory Tract Disease

Related Drug Support Groups

sirolimus, Rapamune